Fluoxetine versus other types of pharmacotherapy for depression.

BACKGROUND Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs) in comparison with other conventional and unconventional antidepressants. However, these studies have produced conflicting findings.Other systematic reviews have considered selective serotonin reuptake inhibitor (SSRIs) as a group which limits the applicability of the indings for fluoxetine alone. Therefore, this review intends to provide specific and clinically useful information regarding the effects of fluoxetine for depression compared with tricyclics (TCAs), SSRIs, serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamineoxidase inhibitors (MAOIs) and newer agents, and other conventional and unconventional agents. OBJECTIVES To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder. SEARCH METHODS We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group Controlled Trials Register (CCDANCTR)to 11May 2012. This register includes relevant RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL) (all years),MEDLINE (1950 to date), EMBASE (1974 to date) and PsycINFO (1967 to date). No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were handsearched. The pharmaceutical company marketing fluoxetine and experts in this field were contacted for supplemental data. SELECTION CRITERIA All RCTs comparing fluoxetine with any other AD (including non-conventional agents such as hypericum) for patients with unipolar major depressive disorder (regardless of the diagnostic criteria used) were included. For trials that had a cross-over design only results from the first randomisation period were considered. DATA COLLECTION AND ANALYSIS Data were independently extracted by two review authors using a standard form. Responders to treatment were calculated on an intention-to-treat basis: dropouts were always included in this analysis. When data on dropouts were carried forward and included in the efficacy evaluation, they were analysed according to the primary studies; when dropouts were excluded from any assessment in the primary studies, they were considered as treatment failures. Scores from continuous outcomes were analysed by including patients with a final assessment or with the last observation carried forward. Tolerability data were analysed by calculating the proportion of patients who failed to complete the study due to any causes and due to side effects or inefficacy. For dichotomous data, odds ratios (ORs) were calculated with 95% confidence intervals (CI) using the random-effects model. Continuous data were analysed using standardised mean differences (SMD) with 95% CI. MAIN RESULTS A total of 171 studies were included in the analysis (24,868 participants). The included studies were undertaken between 1984 and 2012. Studies had homogenous characteristics in terms of design, intervention and outcome measures. The assessment of quality with the risk of bias tool revealed that the great majority of them failed to report methodological details, like the method of random sequence generation, the allocation concealment and blinding. Moreover, most of the included studies were sponsored by drug companies, so the potential for overestimation of treatment effect due to sponsorship bias should be considered in interpreting the results. Fluoxetine was as effective as the TCAs when considered as a group both on a dichotomous outcome (reduction of at least 50% on the Hamilton Depression Scale) (OR 0.97, 95% CI 0.77 to 1.22, 24 RCTs, 2124 participants) and a continuous outcome (mean scores at the end of the trial or change score on depression measures) (SMD 0.03, 95% CI -0.07 to 0.14, 50 RCTs, 3393 participants). On a dichotomousoutcome, fluoxetine was less effective than dothiepin or dosulepin (OR 2.13, 95% CI 1.08 to 4.20; number needed to treat (NNT) =6, 95% CI 3 to 50, 2 RCTs, 144 participants), sertraline (OR 1.37, 95% CI 1.08 to 1.74; NNT = 13, 95% CI 7 to 58, 6 RCTs, 1188 participants), mirtazapine (OR 1.46, 95% CI 1.04 to 2.04; NNT = 12, 95% CI 6 to 134, 4 RCTs, 600 participants) and venlafaxine(OR 1.29, 95% CI 1.10 to 1.51; NNT = 11, 95% CI 8 to 16, 12 RCTs, 3387 participants). On a continuous outcome, fluoxetine was more effective than ABT-200 (SMD -1.85, 95% CI -2.25 to -1.45, 1 RCT, 141 participants) and milnacipran (SMD -0.36, 95% CI-0.63 to -0.08, 2 RCTs, 213 participants); conversely, it was less effective than venlafaxine (SMD 0.10, 95% CI 0 to 0.19, 13 RCTs,3097 participants). Fluoxetine was better tolerated than TCAs considered as a group (total dropout OR 0.79, 95% CI 0.65 to 0.96;NNT = 20, 95% CI 13 to 48, 49 RCTs, 4194 participants) and was better tolerated in comparison with individual ADs, in particular amitriptyline (total dropout OR 0.62, 95% CI 0.46 to 0.85; NNT = 13, 95% CI 8 to 39, 18 RCTs, 1089 participants), and among the newer ADs ABT-200 (total dropout OR 0.18, 95% CI 0.08 to 0.39; NNT = 3, 95% CI 2 to 5, 1 RCT, 144 participants), pramipexole(total dropout OR 0.12, 95% CI 0.03 to 0.42, NNT = 3, 95% CI 2 to 5, 1 RCT, 105 participants), and reboxetine (total dropout OR0.60, 95% CI 0.44 to 0.82, NNT = 9, 95% CI 6 to 24, 4 RCTs, 764 participants). AUTHORS' CONCLUSIONS The present study detected differences in terms of efficacy and tolerability between fluoxetine and certain ADs, but the clinical meaning of these differences is uncertain.Moreover, the assessment of quality with the risk of bias tool showed that the great majority of included studies failed to report details on methodological procedures. Of consequence, no definitive implications can be drawn from the studies' results. The better efficacy profile of sertraline and venlafaxine (and possibly other ADs) over fluoxetine may be clinically meaningful,as already suggested by other systematic reviews. In addition to efficacy data, treatment decisions should also be based on considerations of drug toxicity, patient acceptability and cost.

[1]  G. MacQueen,et al.  Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review , 2010, British Journal of Psychiatry.

[2]  I. Sakinofsky Treating suicidality in depressive illness. Part 2: does treatment cure or cause suicidality? , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[3]  S. Leucht,et al.  Clozapine versus other atypical antipsychotics for schizophrenia. , 2010, The Cochrane database of systematic reviews.

[4]  S. Kutcher,et al.  Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  P. Lewinsohn,et al.  Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  R. Berard,et al.  An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. , 2006, Journal of child and adolescent psychopharmacology.

[7]  M. Weissman,et al.  A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. , 2004, Archives of general psychiatry.

[8]  J. Aubry,et al.  Lithium: Updated Human Knowledge Using an Evidence-Based Approach , 2009, CNS drugs.

[9]  K. Peterson,et al.  Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report , 2010 .

[10]  G. Bernal,et al.  The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. , 1999, Journal of consulting and clinical psychology.

[11]  T. Furukawa,et al.  Metareview on Short-Term Effectiveness and Safety of Antidepressants for Depression: An Evidence-Based Approach to Inform Clinical Practice , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[12]  L Hurst,et al.  Postnatal depression. , 1971, Midwives chronicle.

[13]  F. Scogin,et al.  Cognitive bibliotherapy for mild and moderate adolescent depressive symptomatology. , 1998, Journal of consulting and clinical psychology.

[14]  P. Lewinsohn,et al.  Cognitive-behavioral treatment for depressed adolescents* , 1990 .

[15]  G. Chouinard A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[16]  Richard M Glass,et al.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. , 2005, The Journal of pediatrics.

[17]  M. Weissman,et al.  Efficacy of interpersonal psychotherapy for depressed adolescents. , 1999, Archives of general psychiatry.

[18]  Gary M Diamond,et al.  Attachment-based family therapy for depressed adolescents: a treatment development study. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[19]  J. Geddes,et al.  Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. , 2005, The American journal of psychiatry.

[20]  J. Cohn,et al.  A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[21]  A. Rush,et al.  A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. , 1997, Archives of general psychiatry.

[22]  G. Guyatt,et al.  Validation of an index of the quality of review articles. , 1991, Journal of clinical epidemiology.

[23]  G. Goodwin,et al.  Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. , 2006, The Cochrane database of systematic reviews.

[24]  A. Cipriani,et al.  Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies , 2009, Canadian Medical Association Journal.

[25]  James S. Kahn Comparison of Cognitive-Behavioral, Relaxation, and Self-Modeling Interventions for Depression among Middle-School Students. , 1990 .

[26]  M. Pompili,et al.  Suicide prevention in late life: is there sound evidence for practice. , 2010 .

[27]  I. Goodyer,et al.  Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. , 2010, The British journal of psychiatry : the journal of mental science.

[28]  M. Hotopf,et al.  Fluoxetine versus other types of pharmacotherapy for depression. , 2005, The Cochrane database of systematic reviews.

[29]  N. Ryan,et al.  Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  E. Whitlock,et al.  Screening for Child and Adolescent Depression in Primary Care Settings: A Systematic Evidence Review for the US Preventive Services Task Force , 2009, Pediatrics.

[31]  J. Drazkowski,et al.  Do Antiepileptic Drugs Increase the Risk of Suicidality in Adult Patients With Epilepsy?: A Critically Appraised Topic , 2010, The neurologist.

[32]  R. Apiquián,et al.  A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients , 1997 .

[33]  J. Potvin,et al.  Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. , 1993, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[34]  K. Wagner,et al.  Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[35]  S. Hetrick,et al.  Preventing Suicide in Young People: Systematic Review , 2011, The Australian and New Zealand journal of psychiatry.

[36]  J. Calabrese,et al.  A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. , 2005, The American journal of psychiatry.

[37]  G. Soomro,et al.  Deliberate self harm (and attempted suicide). , 2008, Clinical evidence.

[38]  R. Findling,et al.  A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[39]  J. M. Mullin,et al.  A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. , 1995, The Journal of clinical psychiatry.